Ubrelvy Reduced Impact of Migraine on Daily Activities

Ubrelvy (Ubrogepant; AbbVie, Chicago, IL) showed promise in reducing the impact of migraine on daily activities when taken before the onset of headache pain, according to study results published in Neurology. The study assessed the effects of Ubrelvy treatment in people who could predict an impending migraine attack due to early warning signs such as light sensitivity, etc, before there is any headache pain present.

The study included 518 participants with migraine for ≥1 year who experienced 2 to 8 migraine attacks per month in the 3-month period preceding the start of the study. All participants reported that they could regularly detect warning signs that they may experience a migraine attack within the next few hours. Participants were split into 2 groups, each receiving treatment for 2 of their migraine attacks within a 2-month period using placebo and Ubrelvy at 100 mg in different sequences:

• Participants in the first group received placebo during the first set of migraine warning signs, followed by Ubrelvy for a separate, second set of migraine attack warning signs.
• Participants in the second group received Ubrelvy for their first set of warning signs, and placebo for their second set.

Participants reported the impact of their migraine attacks in limiting daily activity.

• 24 hours after treatment, 65% of participants who received Ubrelvy reported that they were “not at all limited — I could do everything” or “a little limited” compared to 48% of those who received placebo.
• As early as 2 hours posttreatment, individuals who received Ubrelvy were 73% more likely to report having “no disability, able to function” compared with those who received placebo.

“Based on our findings, treatment with ubrogepant may allow people with migraine who experience early warning signs before a migraine occurs to quickly treat migraine attacks in their earliest stages and go about their daily lives with little discomfort and disruption,” said Richard B. Lipton, MD, Professor at Albert Einstein College of Medicine. “This could lead to an improved quality of life for those living with migraine.”